RxDoctor Payments Data

Shelby Potkin, MD

Ophthalmology · Bemidji, MNNPI 1184184277

Payments from drug & device makers

$1,083in general payments, 2019–2025

Across 26 payments — averaging $41.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$520
  • Glaukos Corporation$164
  • AbbVie$153
  • Merz Pharmaceuticals, LLC$85
  • Bausch & Lomb Americas Inc.$49
  • Apellis Pharmaceuticals, Inc.$48
  • plus $64 from 2 others

What the payments were for

  • Food & beverage$95588%
  • Education$12812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,083 in reported general payments places this provider in the 65th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$341,335
Medicare patients
504
Services billed
3,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$7,672
Brimonidine Tartrate51$4,179
Cyclosporine14$2,708
Latanoprost184$2,285
Prednisolone Acetate51$1,952
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat71$1,185
ValacyclovirValacyclovir Hcl28$849
MoxifloxacinMoxifloxacin Hcl47$747
Acetazolamide ErAcetazolamide18$619
ErythromycinErythromycin Base34$428
Timolol Maleate38$362
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha30$347
Dorzolamide Hcl16$315
Ketorolac Tromethamine16$231
Doxycycline Hyclate11$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$153$7,67212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →